Upgrade to SI Premium - Free Trial

Nurix Therapeutics (NRIX)

26.14 +0.82 (3.24%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/9/26)

Latest Headlines

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer August 20, 2026 7:00 AM - Globe NewsWire Form SCHEDULE 13G/A Nurix Therapeutics, Inc. Filed by: Redmile Group, LLC August 14, 2026 4:26 PM - SEC Filing Form SCHEDULE 13G/A Nurix Therapeutics, Inc. Filed by: Vestal Point Capital, LP August 14, 2026 4:13 PM - SEC Filing Form SCHEDULE 13G Nurix Therapeutics, Inc. Filed by: Rubric Capital Management LP August 14, 2026 4:10 PM - SEC Filing Form SCHEDULE 13G Nurix Therapeutics, Inc. Filed by: PRICE T ROWE ASSOCIATES INC /MD/ August 14, 2026 10:39 AM - SEC Filing Form SCHEDULE 13G/A Nurix Therapeutics, Inc. Filed by: Deep Track Capital, LP August 14, 2026 8:37 AM - SEC Filing Nurix (NRIX) PT Raised to $36 at RBC Capital August 10, 2026 7:09 AM - StreetInsider Form 4 Nurix Therapeutics, Inc. For: Aug 05 Filed by: Hansen Gwenn August 5, 2026 6:59 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Hansen Gwenn August 5, 2026 4:28 PM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Aug 04 Filed by: Hansen Gwenn August 5, 2026 6:40 AM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Aug 04 Filed by: van Houte Hans August 4, 2026 9:52 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Hansen Gwenn August 4, 2026 4:34 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: van Houte Hans August 4, 2026 4:34 PM - SEC Filing Nurix earns $10M milestone as Sanofi starts STAT6 degrader trial August 4, 2026 7:00 AM - StreetInsider Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader August 4, 2026 7:00 AM - Globe NewsWire Nurix enrolls first patient in Phase 3 CLL trial of bexobrutideg August 4, 2026 1:00 AM - StreetInsider Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma August 4, 2026 1:00 AM - Globe NewsWire Form 4 Nurix Therapeutics, Inc. For: Aug 03 Filed by: Ring Christine August 3, 2026 5:52 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Ring Christine August 3, 2026 4:39 PM - SEC Filing Form SCHEDULE 13G Nurix Therapeutics, Inc. Filed by: VANGUARD CAPITAL MANAGEMENT LLC July 31, 2026 10:43 AM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Jul 30 Filed by: van Houte Hans July 30, 2026 5:59 PM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Jul 30 Filed by: Ring Christine July 30, 2026 5:56 PM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Jul 30 Filed by: Hansen Gwenn July 30, 2026 5:50 PM - SEC Filing Nurix (NRIX) PT Raised to $38 at Morgan Stanley July 27, 2026 4:36 PM - StreetInsider Nurix (NRIX) PT Raised to $31 at UBS July 22, 2026 7:16 AM - StreetInsider Nurix closes Roche collaboration deal for BTK degrader drug July 21, 2026 4:01 PM - StreetInsider Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunolo July 21, 2026 4:01 PM - Globe NewsWire Nurix (NRIX) PT Raised to $34 at Mizuho July 13, 2026 6:43 AM - StreetInsider Nurix (NRIX) PT Raised to $34 at Mizuho July 10, 2026 12:48 PM - StreetInsider Baird on Nurix (NRIX) Earnings Amid 7% Drop: '2Q Print Solid as Breadth of Development Expands' July 10, 2026 12:08 PM - StreetInsider Nurix (NRIX) PT Raised to $40 at Stifel July 10, 2026 7:38 AM - StreetInsider Nurix (NRIX) PT Raised to $33 at RBC Capital; 'I&I Opportunities Remain Underappreciated' July 10, 2026 7:30 AM - StreetInsider Nurix (NRIX) PT Raised at Truist Securities; 'Roche Partnership Broadens Path to Value Creation' July 10, 2026 7:04 AM - StreetInsider Nurix (NRIX) PT Raised to $34 at H.C. Wainwright July 10, 2026 6:50 AM - StreetInsider Form 10-Q Nurix Therapeutics, Inc. For: May 31 July 9, 2026 4:12 PM - SEC Filing Form 8-K Nurix Therapeutics, Inc. For: Jul 09 July 9, 2026 4:10 PM - SEC Filing Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update July 9, 2026 4:01 PM - StreetInsider Form 4 Nurix Therapeutics, Inc. For: Jul 02 Filed by: Ring Christine July 2, 2026 6:03 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Ring Christine July 2, 2026 4:29 PM - SEC Filing Oppenheimer Reiterates Nurix (NRIX) at Outperform, 'see significant upside potential for NRIX' June 29, 2026 8:20 AM - StreetInsider Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Hansen Gwenn June 25, 2026 6:49 PM - SEC Filing Form 4 Nurix Therapeutics, Inc. For: Jun 25 Filed by: Ring Christine June 25, 2026 6:38 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Ring Christine June 25, 2026 4:25 PM - SEC Filing Form 144 Nurix Therapeutics, Inc. Filed by: Hansen Gwenn June 25, 2026 4:24 PM - SEC Filing Nurix (NRIX) PT Raised to $33 at Baird June 18, 2026 6:14 AM - StreetInsider Stifel Reiterates Buy Rating on Nurix (NRIX) June 15, 2026 9:30 AM - StreetInsider Form 8-K Nurix Therapeutics, Inc. For: Jun 11 June 11, 2026 7:07 AM - SEC Filing Nurix reports updated trial results for BTK degrader in blood cancers June 11, 2026 7:01 AM - StreetInsider Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy June 11, 2026 7:00 AM - Globe NewsWire H.C. Wainwright Reiterates Buy Rating on Nurix (NRIX) June 11, 2026 6:42 AM - StreetInsider UBS Reiterates Buy Rating on Nurix (NRIX) June 9, 2026 9:30 AM - StreetInsider Nurix (NRIX) PT Raised to $32 at Truist Securities June 9, 2026 7:06 AM - StreetInsider Nurix (NRIX) PT Raised to $45 at Jefferies June 8, 2026 1:21 PM - StreetInsider Nurix (NRIX) PT Raised to $45 at Jefferies June 8, 2026 1:21 PM - StreetInsider Oppenheimer on Nurix (NRIX): 'A Big Check for a Big Opportunity' June 8, 2026 10:48 AM - StreetInsider Nurix (NRIX) trades up 20%, RBC says agreement with Roche removes some overhangs, 'We remain buyers' June 8, 2026 9:42 AM - StreetInsider Form 8-K Nurix Therapeutics, Inc. For: Jun 06 June 8, 2026 6:11 AM - SEC Filing Nurix Therapeutics partners with Roche on BTK degrader drug deal June 8, 2026 2:54 AM - StreetInsider Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology June 8, 2026 1:00 AM - Globe NewsWire Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology June 8, 2026 1:00 AM - StreetInsider Full Article List